Abstract
Backgrounds: Drug coated balloons (DCBs) are new on stented-based anti-proliferative drug delivery systems, recently introduced in interventional cardiology. Their primary aim is to transfer an anti-proliferative drug to reduce the subsequent neo-intima hyperplasia and to maintain the normal vessel diameter and function.
Methods: A review of the most recent influential studies about DCBs in all the fields of interventional cardiology has been performed.
Results: As demonstrated by different studies, DCBs have different theoretical advantages over Drug Eluting Stents (DESs), especially for the treatment of some endovascular lesions, as In-Stent Restenosis (ISR), coronary bifurcations, small vessels disease and peripheral artery disease at femoropopliteal and below the knee sites.
Conclusion: Despite the need of further studies are needed to elucidate the optimal use of DCBs their current use in interventional cardiology appears promising.
Keywords: Balloon, angioplasty, drug, interventional, anti-proliferative drug delivery, Drug Coated Balloons (DCBs).
Current Pharmaceutical Design
Title:Drug-Coated Balloons Applications in Interventional Cardiology
Volume: 24 Issue: 4
Author(s): Gianluca Rigatelli*Marco Zuin
Affiliation:
- Section of Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo,Italy
Keywords: Balloon, angioplasty, drug, interventional, anti-proliferative drug delivery, Drug Coated Balloons (DCBs).
Abstract: Backgrounds: Drug coated balloons (DCBs) are new on stented-based anti-proliferative drug delivery systems, recently introduced in interventional cardiology. Their primary aim is to transfer an anti-proliferative drug to reduce the subsequent neo-intima hyperplasia and to maintain the normal vessel diameter and function.
Methods: A review of the most recent influential studies about DCBs in all the fields of interventional cardiology has been performed.
Results: As demonstrated by different studies, DCBs have different theoretical advantages over Drug Eluting Stents (DESs), especially for the treatment of some endovascular lesions, as In-Stent Restenosis (ISR), coronary bifurcations, small vessels disease and peripheral artery disease at femoropopliteal and below the knee sites.
Conclusion: Despite the need of further studies are needed to elucidate the optimal use of DCBs their current use in interventional cardiology appears promising.
Export Options
About this article
Cite this article as:
Rigatelli Gianluca *, Zuin Marco , Drug-Coated Balloons Applications in Interventional Cardiology, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666171227212112
DOI https://dx.doi.org/10.2174/1381612824666171227212112 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Safety and Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) for the Treatment of Persistent Macular Edema Secondary to Retinal Vein Occlusion in Eyes Previously Treated with Anti-Vascular Endothelial Growth Factors
Current Drug Safety Heart Disease Prediction System using Ensemble of Machine Learning Algorithms
Recent Patents on Engineering Clopidogrel Generic Formulations in the Era of New Antiplatelets: A Systematic Review
Current Vascular Pharmacology Endothelial Dysfunction and Inflammation in Ischemic Stroke Pathogenesis
Current Pharmaceutical Design Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence
Current Pharmaceutical Design Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points
Letters in Drug Design & Discovery Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling
Current Medicinal Chemistry Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Current Pharmaceutical Design The Association Between Diabetes and Cognitive Function in Later Life
Current Aging Science Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Role of Renin-Angiotensin System in Vascular Endothelial Dysfunction of Pregnancy-Induced Hypertension
Current Hypertension Reviews Protease Inhibitors in the Clinic
Medicinal Chemistry Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors
Current Medicinal Chemistry New Treatments for COPD in the Elderly
Current Pharmaceutical Design